Fda grants orphan drug designation to omeros' masp-3 inhibitor oms906 for treatment of paroxysmal nocturnal hemoglobinuria

Seattle--(business wire)--omeros corporation today announced that oms906 has received orphan drug designation from the u.s. food and drug administration (fda) for the treatment of paroxysmal nocturnal hemoglobinuria (pnh). oms906 targets mannan-binding lectin-associated serine protease-3 (masp-3), the key activator of the alternative pathway of the complement system. masp-3 converts pro-complement factor d (pro-cfd) to mature cfd. pnh is a rare, life-threatening disease characterized by red blo
OMER Ratings Summary
OMER Quant Ranking